| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Windtree Therapeutics (OTC:WINT) reported quarterly losses of $(1.08) per share. This is a 99.49 percent increase over losses o...
-SEC Filing
Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and...
Publicly traded companies are increasingly integrating cryptocurrencies other than Bitcoin (CRYPTO: BTC), into their treasuries...
Up to $700 Million Committed to BNB Acquisitions, Reinforcing Innovative Crypto Treasury StrategyNinety Nine Percent of the pro...
Up to $700 Million Committed to BNB Acquisitions, Reinforcing Innovative Crypto Treasury StrategyNinety Nine Percent of the pro...
Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT) is pleased to announce a strategic p...